Pioneer Family Office’s AbbVie ABBV Stock Holding History

Pioneer Family Office’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$307K	Buy	+1,221	New	+$263K	0.16%	28

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Pioneer Family Office's ABBV Position: Q2 2026 in Review

Pioneer Family Office opened a new position in AbbVie (ABBV) in Q2 2026: 1,221 shares worth $307K. The stake represents 0.16% of the portfolio and ranks #28 among its holdings.

4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Pioneer Family Office held 1,221 shares of AbbVie worth $307K as of Q2 2026.
AbbVie was a new Pioneer Family Office position in Q2 2026.
AbbVie made up 0.16% of Pioneer Family Office's portfolio in Q2 2026, its #28 holding.
4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Pioneer Family Office's 13F filing for Q2 2026, filed 28 Jul 2026.